SN52 T38460

Product Introduction
Bioactivity


英文名: SN52

描述: SN52 is a powerful, competitive, and cell-permeable inhibitor of NF-κB2. It is a variant of the SN50 peptide. SN52 effectively prevents the nuclear translocation of p52-RelB heterodimers, exhibiting a robust radiosensitization effect on prostate cancer cells. This compound holds significant potential for cancer research purposes.

体外活性: SN52 (40 μg/ml; 30 mins before DMXAA) inhibits DMXAA-induced nuclear translocation of RelB in BMDCs[1].SN52 does not change the activation of canonical NF-κB signaling. The nuclear translocation of RelB is increased in DCs isolated from irradiated tumors, and SN52 abolishes this activation in activated DC cells[1].SN52 (40 μg/mL; 30 mins before co-cultured with irradiated or non-irradiated MC38 cells) inhibits the non-canonical NF-κB and increases?Ifn-b?expression in BMDCs stimulated with irradiated tumor cells[1].

体内活性: SN52 (intrathecal injection; 40 μg/ml; day-1, day 1 and day 3 of 20Gy radiation of radiation) combines with IR enhances anti-tumor immune functions of both DCs and CD8 + T cells and subsequently reduced tumor burden more effectively compared with IR alone[1]. Animal Model: Tumor mice model[1]Dosage: 40 μg Administration: Intrathecal injection; 40 μg; day-1, day 1 and day 3 of 20Gy radiation of radiation Result: Reduced tumor burden than IR group alone.Induced non-canonical NF-κB inhibition and potentiates the anti-tumor effect of IR.

存储条件: keep away from moisturePowder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: SN 52 | SN52 | SN-52

SN52 T38460信息由TargetMol中国为您提供，如您想了解更多关于SN52 T38460报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途